Aktis Oncology

AKTS · NASDAQ

$16.08+$0.97 (+6.42%)TodayMarket closed · Oct 20, 6:38 PM ET

Prev close $15.11

AKTS analyst rating

BuyConsensus of 8 analysts over the last 12 months. 100% rate it a buy.

Strong buy1
Buy7
Hold0
Underperform0
Sell0

12-month price target · 10 analysts

Average $37.01 (+130.2% upside)

Low: $33.33
Now: $16.08
High: $42.00

Upgrades and downgrades

The latest rating actions, newest first

AKTS analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Wedbush	Oct 2, 2026	Maintains	Outperform	$35.00	46%
Oppenheimer	Sep 9, 2026	Initiates	Outperform	$40.00	33%
Wedbush	Aug 19, 2026	Initiates	Outperform	$35.00	46%
BMO Capital	Aug 19, 2026	Initiates	Outperform	$37.00	55%
JP Morgan	Jul 14, 2026	Maintains	Overweight	$30.00 → $33.00	57%
Raymond James	Jun 16, 2026	Initiates	Strong Buy	$40.00	51%
HC Wainwright & Co.	Jun 2, 2026	Maintains	Buy	$33.00 → $35.00	41%
William Blair	Apr 29, 2026	Initiates	Outperform	—	0%
HC Wainwright & Co.	Mar 31, 2026	Maintains	Buy	$30.00 → $33.00	41%
HC Wainwright & Co.	Mar 9, 2026	Initiates	Buy	$30.00	41%

The case for and against

Updated Oct 15, 2026

Bull case

Aktis Oncology is viewed favorably because it combines two clinically validated targets—Nectin-4 and B7-H3—with differentiated 225Ac miniprotein radioconjugates that have shown strong preclinical tumor control, broad imaging uptake, and low normal-tissue exposure. The lead asset, AKY-1189, has demonstrated greater activity than Padcev in low-Nectin-4 models and is on track for preliminary data from NECTINIUM-2 in 1Q27, while AKY-2519 has shown 92% tumor-growth inhibition in NSCLC xenografts and proof-of-concept across mCRPC and lung cancers. The company’s outlook is further strengthened by multiple 225Ac supply agreements, a planned internal cGMP facility expected online in 2H26, and an estimated ~$2.3B in combined worldwide sales by 2035 across its two clinical-stage programs.

Bear case

Aktis Oncology is a clinical-stage oncology company with no approved products, so its value depends heavily on unproven radiopharmaceutical programs and future collaboration revenue rather than recurring commercial sales. The bearish view is driven by the high risk that AKY-1189 and AKY-2519 fail to show differentiated efficacy and tolerability in solid tumors, especially against established standards like Padcev, which delivered 2025 worldwide sales of about $2.6B and strong survival gains in urothelial carcinoma. Added downside comes from possible clinical delays, isotope supply or manufacturing constraints, reimbursement uncertainty, and long-term dilution risk, while the DCF assumes only a 20% probability of approval for each lead program.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.